Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections

DUBLIN, Ireland , Nov. 01, 2018 (GLOBE NEWSWIRE) —   Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced it has submitted a New Drug Application (NDA)

READ FULL TEXT